Table 2. Clinical parameters.
Hypertension only |
Polycystic kidney disease with hypertension |
||||||||||||||||||
Placebo (n = 6) |
50 mg levodopa (n = 12) |
100 mg levodopa (n = 8) |
Placebo (n = 12) |
50 mg levodopa (n = 12) |
100 mg levodopa (n = 12) |
||||||||||||||
Baseline | 2 h | 7 day | Baseline | 2 h | 7 day | Baseline | 2 h | 7 day | Baseline | 2 h | 7 day | Baseline | 2 h | 7 day | Baseline | 2 h | 7 day | ||
Age, yrs | 36.8 ± 2.7 | 36.8 ± 1.6 | 36.5 ± 1.9 | 37.1 ± 1.9 | 37.4 ± 1.4 | 37.4 ± 1.5 | |||||||||||||
BMI, kg/m2 | 25.5 ± 1.2 | 25.9 ± 1.1 | 23.1 ± 1.5 | 28.1 ± 1.3 | 27.1 ± 1.2 | 27.1 ± 1.2 | |||||||||||||
MAP, mmHg | 108.9 ± 1.3 | 106.4 ± 1.0 | 108.6 ± 1.2 | 108.2 ± 1.0 | 104.7 ± 1.3 | 104.7 ± 1.3 | 108.8 ± 0.8 | 104.8 ± 1.2 | 104.4 ± 1.1 | 107.4 ± 0.9 | 106.8 ± 1.0 | 106.7 ± 0.9 | 107.4 ± 0.8 | 104.1 ± 1.5 | 104.9 ± 1.0 | 108.0 ± 0.7 | 107.0 ± 0.8 | 104.1 ± 1.2 | |
SBP, mmHg | 136.7 ± 1.7 | 136.2 ± 1.1 | 135.8 ± 1.5 | 136.2 ± 1.1 | 132.5 ± 1.3 | 132.5 ± 1.3 | 137.5 ± 1.3 | 133.1 ± 1.6 | 133.1 ± 1.6 | 134.6 ± 1.0 | 133.8 ± 0.9 | 134.2 ± 1.0 | 135.3 ± 0.7 | 133.4 ± 1.0 | 132.8 ± 0.9 | 135.3 ± 0.7 | 135.3 ± 0.7 | 132.8 ± 1.0 | |
DBP, mmHg | 95.0 ± 1.3 | 93.3 ± 1.1 | 95.0 ± 1.3 | 94.2 ± 1.0 | 90.8 ± 1.4 | 90.8 ± 1.4 | 94.4 ± 0.6 | 90.6 ± 1.1 | 90.0 ± 0.9 | 93.8 ± 1.1 | 93.3 ± 1.1 | 92.9 ± 1.0 | 93.4 ± 0.9 | 89.4 ± 1.0 | 90.9 ± 1.0 | 94.4 ± 0.8 | 92.8 ± 0.9 | 89.7 ± 1.3 | |
HR, beats/min | 72 ± 3.2 | 71.3 ± 3.4 | 72 ± 3.4 | 72.7 ± 2.9 | 73.2 ± 2.7 | 72.7 ± 2.9 | 75 ± 2.3 | 73.8 ± 2.4 | 73.5 ± 2.5 | 68.5 ± 1.9 | 67.7 ± 1.8 | 68.2 ± 1.9 | 68.8 ± 1.5 | 68.9 ± 1.4 | 67.8 ± 1.3 | 68.3 ± 1.4 | 67.8 ± 1.3 | 71.1 ± 1.1 | |
Creatinin, mg/dL | 0.75 ± 0.03 | N/A | 0.75 ± 0.03 | 0.79 ± 0.03 | N/A | 0.82 ± 0.02 | 0.81 ± 0.03 | N/A | 0.83 ± 0.03 | 1.32 ± 0.04 | N/A | 1.32 ± 0.04 | 1.28 ± 0.04 | N/A | 1.28 ± 0.03 | 1.19 ± 0.03 | N/A | 1.18 ± 0.04 | |
Urea, mg/dL | 27.8 ± 1.0 | N/A | 28.3 ± 1.2 | 27.5 ± 1.1 | N/A | 27.6 ± 1.3 | 28.1 ± 0.9 | N/A | 28.6 ± 1.1 | 29.5 ± 0.8 | N/A | 29.7 ± 0.9 | 28.1 ± 0.9 | N/A | 28.4 ± 1.0 | 28.3 ± 0.9 | N/A | 28.6 ± 0.9 | |
Ca2+, mg/dL | 9.9 ± 0.2 | N/A | 9.8 ± 0.2 | 9.8 ± 0.1 | N/A | 9.8 ± 0.1 | 9.8 ± 0.1 | N/A | 9.8 ± 0.1 | 9.1 ± 0.1 | N/A | 9.0 ± 0.1 | 9.1 ± 0.1 | N/A | 9.1 ± 0.1 | 8.9 ± 0.1 | N/A | 9.1 ± 0.1 | |
Na+, mEq/L | 145.2 ± 1.1 | N/A | 145.7 ± 1.3 | 144.3 ± 1.0 | N/A | 144.7 ± 1.0 | 143.8 ± 0.8 | N/A | 143.4 ± 1.2 | 142.2 ± 1.2 | N/A | 142.5 ± 1.1 | 142.3 ± 0.9 | N/A | 142.9 ± 1.1 | 142.5 ± 0.9 | N/A | 142.6 ± 0.9 | |
K+, mEq/L | 4.1 ± 0.1 | N/A | 4.1 ± 0.2 | 4.3 ± 0.1 | N/A | 4.3 ± 0.1 | 4.4 ± 0.1 | N/A | 4.4 ± 0.2 | 4.0 ± 0.1 | N/A | 4.0 ± 0.1 | 4.0 ± 0.1 | N/A | 4.0 ± 0.1 | 4.0 ± 0.1 | N/A | 4.1 ± 0.1 | |
Albumin, g/dL | 3.6 ± 0.13 | N/A | 3.6 ± 0.04 | 3.6 ± 0.03 | N/A | 3.6 ± 0.02 | 3.6 ± 0.03 | N/A | 3.7 ± 0.03 | 3.5 ± 0.03 | N/A | 3.6 ± 0.03 | 3.5 ± 0.02 | N/A | 3.5 ± 0.03 | 3.5 ± 0.03 | N/A | 3.5 ± 0.03 | |
ALT, IU/L | 9.8 ± 0.9 | N/A | 9.9 ± 0.9 | 8.3 ± 0.6 | N/A | 8.6 ± 0.7 | 8.9 ± 0.6 | N/A | 8.9 ± 0.5 | 12.1 ± 2.0 | N/A | 12.8 ± 2.0 | 12.2 ± 1.8 | N/A | 12.2 ± 1.8 | 13.3 ± 1.9 | N/A | 13.0 ± 1.6 | |
AST, IU/L | 9.8 ± 0.8 | N/A | 10.2 ± 0.9 | 9.3 ± 1.0 | N/A | 9.2 ± 0.9 | 9.9 ± 1.0 | N/A | 9.9 ± 0.9 | 10.6 ± 2.0 | N/A | 10.4 ± 1.8 | 10.7 ± 1.9 | N/A | 10.6 ± 1.7 | 11.1 ± 1.6 | N/A | 11.5 ± 1.4 | |
AP, IU/L | 11.5 ± 1.3 | N/A | 11.9 ± 1.2 | 11.8 ± 0.9 | N/A | 11.6 ± 0.9 | 11.4 ± 0.9 | N/A | 11.2 ± 0.8 | 15.5 ± 2.2 | N/A | 15.4 ± 2.3 | 15.2 ± 2.0 | N/A | 15.0 ± 1.9 | 15.6 ± 1.7 | N/A | 15.4 ± 1.7 | |
Bilirubin, mg/dL | 0.5 ± 0.02 | N/A | 0.6 ± 0.02 | 0.6 ± 0.02 | N/A | 0.6 ± 0.02 | 0.6 ± 0.04 | N/A | 0.6 ± 0.02 | 0.6 ± 0.02 | N/A | 0.5 ± 0.02 | 0.6 ± 0.02 | N/A | 0.6 ± 0.02 | 0.5 ± 0.02 | N/A | 0.6 ± 0.02 |
Patient data and serum parameters were tabulated on the table. Mean arterial pressure was calculated as (2 × diastolic + systolic) /3. ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotransferase; BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; HR: heart rate; MAP: mean arterial pressure; N/A: not available.